Get the Stockscreener App
53.26
2.74%
-1.50
After Hours:
53.26
Praxis Precision Medicines Inc stock is traded at $53.26, with a volume of 243.19K.
It is down -2.74% in the last 24 hours and up +32.39% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$54.76
Open:
$54.86
24h Volume:
243.19K
Relative Volume:
0.52
Market Cap:
$1.12B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-5.8081
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-2.06%
1M Performance:
+32.39%
6M Performance:
+87.07%
1Y Performance:
-14.06%
1-Day Range:
$51.99
$55.10
1-Week Range:
$50.31
$55.79
52-Week Range:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
53.26 | 1.15B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Price momentum metrics for Praxis Precision Medicines Inc. explainedQuarterly Profit Summary & Short-Term Trading Alerts - newser.com
Multi asset correlation models including Praxis Precision Medicines Inc.Weekly Earnings Recap & Safe Entry Momentum Tips - newser.com
Praxis Precision Medicines (NASDAQ:PRAX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
How institutional ownership impacts Praxis Precision Medicines Inc. stockExit Point & Verified High Yield Trade Plans - newser.com
Did the ReCode Partnership Just Shift Praxis Precision Medicines' (PRAX) Innovation Narrative in Neuroscience? - Yahoo Finance
Assessing Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo
Why Praxis Precision Medicines Inc. is moving todayJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Published on: 2025-10-06 01:53:19 - newser.com
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Is Praxis Precision Medicines Inc a good long term investmentOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in
Visual analytics tools that track Praxis Precision Medicines Inc. performance2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
Real time pattern detection on Praxis Precision Medicines Inc. stockTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Praxis Precision Medicines Inc. stock trend forecastQuarterly Profit Report & Free Weekly Watchlist of Top Performers - newser.com
Praxis Precision Medicines (PRAX): Evaluating Valuation Potential Following Brain-Targeted Delivery Collaboration - Sahm
Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesJuly 2025 Momentum & Low Risk Investment Opportunities - newser.com
Real time scanner hits for Praxis Precision Medicines Inc. explainedQuarterly Growth Report & Real-Time Market Sentiment Reports - newser.com
What technical models suggest about Praxis Precision Medicines Inc.’s comebackGap Up & Consistent Profit Focused Trading Strategies - newser.com
Could PRAX's Focus on Delivery Innovation Signal a Shift in CNS Therapy Ambitions? - Sahm
Chart based analysis of Praxis Precision Medicines Inc. trendsJuly 2025 EndofMonth & Intraday High Probability Alerts - newser.com
Will earnings trigger a reversal in Praxis Precision Medicines Inc.July 2025 Institutional & High Accuracy Buy Signal Tips - newser.com
Published on: 2025-10-02 21:58:13 - newser.com
Risk vs reward if holding onto Praxis Precision Medicines Inc.July 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - newser.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule - MarketScreener
4,200 RSUs: Praxis Precision Medicines Grants Awards to 3 New Hires, Vesting Over 4 Years - Stock Titan
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com
Published on: 2025-10-01 08:22:08 - newser.com
Published on: 2025-09-30 15:59:01 - newser.com
Should You Stay Invested in Aspinwall and Company Limited for the Long HaulStock Buyback Announcements & Affordable Trading Plans - earlytimes.in
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update - Business Wire
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Option Exercise |
56.94 |
7,583 |
431,776 |
18,540 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):